The characteristics of patients with chronic hepatitis B in Turkey

dc.contributor.authorKemal Celen M.
dc.contributor.authorTekin Koruk S.
dc.contributor.authorAygen B.
dc.contributor.authorDal T.
dc.contributor.authorKarabay O.
dc.contributor.authorTosun S.
dc.contributor.authorKoksal I.
dc.date.accessioned2024-04-24T18:46:14Z
dc.date.available2024-04-24T18:46:14Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim To evaluate the characteristics of patients with hepatitis B virus (HBV) infection and summarize the treatment modalities. Methods By September 30, 2011 the data of 7871 HBsAg (+) patients were complied and analysed according to demographic and medical records (age, sex, laboratory tests, treatment with antiviral agents) in thirty centres of Turkey. Results Of the 7871 patients 3078 (39.1%) were females; mean (standard deviation) age was 35 (14) years, 3180 (40.4%) were HBsAg positive (+) after admission to a hospital, 1488 (18.9%) after blood donation and 967 (11.9%) were found during routine screening. The HBV prevalence among relatives of HBsAg (+) patients was 1764 (22.4%), and most frequently infected family members were siblings and mothers, 4961 (63.0%) and 2149 (27.3%), respectively). Anti-HDV was negative in 7407 94.1% of patients. Three-fourths of the patients 6383 (81.1%) were HBeAg negative (-). Mean (SD) ALT was 85.8 (266.4) U/L. Majority of patients, 5588 (71.0%) were chronic hepatitis-B patients under treatment, while 2283 (29.0%) were asymptomatic carriers without treatment and only 165 (2.1%) of patients were cirrhotic and 6612 (84.0%) of those were compensated. One-third of the patients 2983 (37.9%) were under a combined treatment, while others were under monotherapy. Lamivudine, entecavir and adefovir were the most frequently used oral therapies, used for 2583 (32.8%), 11.6% and 787 (10.0%) of patients, respectively), while 2975 (37.8%) of patients were under interferon treatment. Conclusion Hepatitis B is still a problem in our country. First task of the physicians and our state should be to prevent the development and spread of the disease with education and vaccination programs, safe blood transfusions, and control of barbers.en_US
dc.identifier.endpage98en_US
dc.identifier.issn1840-0132
dc.identifier.issue1en_US
dc.identifier.pmid24496347
dc.identifier.scopus2-s2.0-84893219442
dc.identifier.scopusqualityQ2
dc.identifier.startpage94en_US
dc.identifier.urihttps://hdl.handle.net/11468/25122
dc.identifier.volume11en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherMedical Association of Zenica-Doboj Cantonen_US
dc.relation.ispartofMedicinski Glasnik
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBlood Donoren_US
dc.subjectHepadnaviridae İnfectionsen_US
dc.subjectPrevalenceen_US
dc.titleThe characteristics of patients with chronic hepatitis B in Turkeyen_US
dc.titleThe characteristics of patients with chronic hepatitis B in Turkey
dc.typeArticleen_US

Dosyalar